Compare CVS Health Corp (CVS) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs State Street SPDR S&P Homebuilders ETF — how do they compare? CVS Health Corp trades at $105.88 (market cap $135.48B), while State Street SPDR S&P Homebuilders ETF trades at $108.25. The key difference: CVS Health Corp pays a 2.51% dividend while State Street SPDR S&P Homebuilders ETF pays none, and CVS Health Corp is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| CVS | XHB | |
|---|---|---|
Market Cap | $135.48B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $106.18 | $121.36 |
52-Week Low | $58.75 | $94.86 |
Enterprise Value | $202.02B | — |
Dividend Yield | 2.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
XHB trades at $107.07, down 1.42% amid bearish technical signals, with support at $104 and resistance at $110. The ETF faces mixed housing data with declining existing home sales but potential tailwinds from new housing legislation. Key indicators show oversold short-term RSI but strong bearish momentum from ADX.
Outlook is cautious due to high mortgage rates and record home prices pressuring demand, though legislative support for homebuilders offers upside. Risks include interest rate sensitivity and economic slowdowns. Analyst sentiment is neutral with focus on housing market recovery timing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
